These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31652991)

  • 1. The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin.
    Traini C; Vannucchi MG
    Toxins (Basel); 2019 Oct; 11(11):. PubMed ID: 31652991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder.
    Chen SF; Chang CH; Kuo HC
    Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27249005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders.
    Lin YH; Chiang BJ; Liao CH
    Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nerve sprouting and neurogenic inflammation characterize the neurogenic detrusor overactive bladder of patients no longer responsive to drug therapies.
    Traini C; Del Popolo G; Faussone-Pellegrini MS; Guasti D; Catarinicchia S; Vannucchi MG
    J Cell Mol Med; 2019 Jun; 23(6):4076-4087. PubMed ID: 30945429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.
    Conte A; Giannantoni A; Proietti S; Giovannozzi S; Fabbrini G; Rossi A; Porena M; Berardelli A
    Eur J Neurol; 2012 May; 19(5):725-32. PubMed ID: 22212295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.
    Popat R; Apostolidis A; Kalsi V; Gonzales G; Fowler CJ; Dasgupta P
    J Urol; 2005 Sep; 174(3):984-9. PubMed ID: 16094019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
    Cruz F; Nitti V
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of botulinum neurotoxin on the urinary bladder: novel insights on mechanism of action.
    Vianello A; Proietti S; Giannantoni A
    Minerva Urol Nefrol; 2010 Sep; 62(3):259-71. PubMed ID: 20940695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
    Nambiar A; Lucas M
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.
    Linsenmeyer TA
    J Spinal Cord Med; 2013 Sep; 36(5):402-19. PubMed ID: 23941788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.
    Apostolidis A; Popat R; Yiangou Y; Cockayne D; Ford AP; Davis JB; Dasgupta P; Fowler CJ; Anand P
    J Urol; 2005 Sep; 174(3):977-82; discussion 982-3. PubMed ID: 16094018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
    Chen G; Liao L
    Int Urol Nephrol; 2011 Sep; 43(3):655-62. PubMed ID: 21110094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study.
    Maignel J; Martin V; Assaly R; Vogt ML; Retailleau K; Hornby F; Laugerotte A; Lezmi S; Denys P; Krupp J; Joussain C
    Toxins (Basel); 2022 Jan; 14(2):. PubMed ID: 35202105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment.
    Alloussi SH; Lang Ch; Eichel R; Al-Kaabneh A; Seibold J; Schwentner C; Alloussi S
    World J Urol; 2012 Jun; 30(3):367-73. PubMed ID: 21842216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of onobotulinumtoxinA as a therapeutic option for pediatric neurogenic detrusor overactivity.
    Peard LM; Pope JC; Dmochowski R
    Expert Rev Neurother; 2023; 23(9):763-774. PubMed ID: 37556757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
    Mangera A; Apostolidis A; Andersson KE; Dasgupta P; Giannantoni A; Roehrborn C; Novara G; Chapple C
    Eur Urol; 2014 May; 65(5):981-90. PubMed ID: 24239446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
    Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
    Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the suspension of neurogenic detrusor overactivity treatment with botulinum toxin due to the COVID-19 pandemic.
    Freitas Ferreira E; Silva R; Ferreira A; Paz Carvalho M; Vale P; Faria F
    Urologia; 2023 May; 90(2):387-394. PubMed ID: 35880710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
    Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J
    J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Video-Urodynamic Characteristics and Predictors of Switching from Botulinum Neurotoxin a Injection to Augmentation Enterocystoplasty in Spinal Cord Injury Patients.
    Lin CC; Kuo HC
    Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.